As CBD Journal reported back in June, the FDA has approved the use of a CBD-based drug called Epidiolex for the treatment of two of the hardest-to-treat forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome. According to a story in the New York Times, makers of the drug, British-based GW Pharmaceuticals, says the drug will cost roughly $32,500 per year.
FDA officials finally approved the world’s first CBD-based drug, Epidiolex, developed by pharmaceutical-maker by GW Pharmaceuticals. The drug is designed for use in treating two severe forms of childhood epilepsy and is the very first FDA-approved medication that contains a purified cannabinoid derived from cannabis. Moreover, it is the first FDA approval of any drug specifically meant to treat Dravet syndrome, one of the aforementioned forms of epilepsy.